UNSPSC 51143701: Liver/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143701 Liver/phenobarbital is a Commodity code with minimal alignment to recent state and local procurement activity. The code nominally covers pharmaceutical preparations containing liver extract and phenobarbital compounds, but recent opportunities tagged under this code do not reflect purchases of those products. Instead, state and local solicitations currently show activity in naloxone distribution, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products—none of which fall within the liver/phenobarbital scope. This mismatch between the code's intended use and actual procurement demand signals either miscoding by issuing bodies or a market shift away from liver/phenobarbital formulations toward broader emergency response and generic pharmaceutical procurement. The issuing bodies in recent records span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP), indicating that the activity tagged here reflects general pharmaceutical sourcing rather than a specific phenobarbital-based product line.

Geographic activity appears concentrated in Florida and Texas, with multi-state reach through cooperative purchasing vehicles. Recent opportunities include Seminole County's IFB60459723LAS (naloxone and drug deactivation systems, due July 26, 2023), Texas HHS Commission's RFI HHS0017013 (direct-to-manufacturer prescription programs, response deadline April 3, 2026), and MMCAP's S1070000015802 multi-source pharmaceutical RFP (due March 26, 2026, serving Minnesota, Oregon, and participating jurisdictions). The code shows no traceable demand for the liver/phenobarbital formulations it nominally describes, suggesting that pursuit under this classification would require clarification with the issuing body about actual product requirements before bid preparation.